These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 23731629)

  • 1. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intradermal and virosomal influenza vaccines for preventing influenza hospitalization in the elderly during the 2011-2012 influenza season: a comparative effectiveness study using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Díez-Domingo J
    Vaccine; 2014 Sep; 32(42):5447-54. PubMed ID: 25131737
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is the adjuvanted influenza vaccine more effective than the trivalent inactivated vaccine in the elderly population? Results of a case-control study.
    Spadea A; Unim B; Colamesta V; Meneghini A; D'Amici AM; Giudiceandrea B; La Torre G
    Vaccine; 2014 Sep; 32(41):5290-4. PubMed ID: 25087677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis.
    Domnich A; Arata L; Amicizia D; Puig-Barberà J; Gasparini R; Panatto D
    Vaccine; 2017 Jan; 35(4):513-520. PubMed ID: 28024956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvanted versus nonadjuvanted influenza vaccines and risk of hospitalizations for pneumonia and cerebro/cardiovascular events in the elderly.
    Lapi F; Marconi E; Simonetti M; Baldo V; Rossi A; Sessa A; Cricelli C
    Expert Rev Vaccines; 2019 Jun; 18(6):663-670. PubMed ID: 31155968
    [No Abstract]   [Full Text] [Related]  

  • 6. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly.
    Van Buynder PG; Konrad S; Van Buynder JL; Brodkin E; Krajden M; Ramler G; Bigham M
    Vaccine; 2013 Dec; 31(51):6122-8. PubMed ID: 23933368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
    Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
    Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects.
    Frey SE; Reyes MR; Reynales H; Bermal NN; Nicolay U; Narasimhan V; Forleo-Neto E; Arora AK
    Vaccine; 2014 Sep; 32(39):5027-34. PubMed ID: 25045825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk.
    Durando P; Icardi G; Ansaldi F
    Expert Opin Biol Ther; 2010 Apr; 10(4):639-51. PubMed ID: 20218923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly.
    de Bruijn I; Meyer I; Gerez L; Nauta J; Giezeman K; Palache B
    Vaccine; 2007 Dec; 26(1):119-27. PubMed ID: 18063446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of the MF59-adjuvanted influenza vaccine in preventing emergency admissions for pneumonia in the elderly over 64 years of age.
    Puig-Barberà J; Diez-Domingo J; Pérez Hoyos S; Belenguer Varea A; González Vidal D
    Vaccine; 2004 Dec; 23(3):283-9. PubMed ID: 15530669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
    Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
    J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
    McGovern I; Chastek B; Bancroft T; Webb N; Imran M; Pelton SI; Haag MDM
    Int J Infect Dis; 2024 Sep; 146():107160. PubMed ID: 38969330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic and Health impact of influenza vaccination with adjuvant MF59 in population over 64 years in Spain].
    Pérez-Rubio A; Eiros JM
    Rev Esp Quimioter; 2018 Feb; 31(1):43-52. PubMed ID: 29355006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.
    O'Hagan DT
    Expert Rev Vaccines; 2007 Oct; 6(5):699-710. PubMed ID: 17931151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective cohort study assessing relative effectiveness of adjuvanted versus high-dose trivalent influenza vaccines among older adults in the United States during the 2018-19 influenza season.
    Pelton SI; Divino V; Postma MJ; Shah D; Mould-Quevedo J; DeKoven M; Krishnarajah G
    Vaccine; 2021 Apr; 39(17):2396-2407. PubMed ID: 33810903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis.
    Banzhoff A; Nacci P; Podda A
    Gerontology; 2003; 49(3):177-84. PubMed ID: 12679609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study.
    Della Cioppa G; Vesikari T; Sokal E; Lindert K; Nicolay U
    Vaccine; 2011 Nov; 29(47):8696-704. PubMed ID: 21906647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of introducing an MF59-adjuvanted trivalent influenza vaccine for older adults in Argentina.
    Nguyen VH; Vizzotti C; Uruena A; Giglio N; Magneres C; Richmond H
    Vaccine; 2020 Apr; 38(20):3682-3689. PubMed ID: 32249017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.